Think All Hedge Funds Love Valeant? Meet This Short-Seller
Raging Capital is so skeptical of the controversial drug maker that it’s short the company’s equity and debt.
Stephen TaubAugust 15, 2016
As hedge funds hurriedly file their second quarter stock holdings with the Securities and Exchange Commission ahead of Monday’s deadline, observers are no doubt very interested in seeing who bought, sold or held onto
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.